Gesynta Pharma
- is a privately-held pharmaceutical company developing novel oral treatments for patients with chronic inflammatory conditions
- is based in Stockholm and has a virtual set-up with a management team highly experienced in drug development
Science
Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme downstream of the cyclooxygenase enzymes, is upregulated by inflammatory stimuli and is involved in the inflammatory processes of cardiovascular diseases and cancer.
Use of mPGES-1 inhibitors in microvascular disease:Cardiovascular morbidity and mortality are common in chronic inflammatory diseases due to vascular inflammation and endothelial dysfunction.
Selective deletion of mPGES-1 activity leads to anti-inflammatory, vasodilatory and platelet inhibitory effects.
GS-248 –A First in Class opportunity with combined anti-inflammatory, vasodilatory and platelet inhibitory effects
Our research has revealed novel uses for mPGES-1 inhibitors in the treatment of microvascular inflammation and represents a unique opportunity for development of new medicines.
Products
Gesynta Pharma develops selective mPGES-1 inhibitors for microvascular diseases in chronic inflammatory conditions with the clinical candidate, GS-248, entering clinical phase development in mid 2019.
GS-248, is a highly potent mPGES-1 inhibitor with excellent drug-like properties in development for a first indication, which is an orphan disease with few approved treatments and those available have severe side effects which are limiting their use.
Drug Discovery. We also recently acquired a late-stage drug discovery project, including several proprietary molecules originating from a major pharmaceutical company, which will broaden the project pipeline with potent and druggable molecules to be explored for treatment of additional, broader cardiovascular diseases and cancer.
Company
Gesynta Pharma was founded on the basis of:
- access to potent and selective mPGES-1 inhibitors for pharmacological research and clinical development
- proprietary knowledge of novel aspects of biological/medical effects caused by mPGES-1 inhibition leading to new opportunities in novel indications
- a team with extensive experience
Gesynta Pharma has been supported by Karolinska Institutet Innovation AB, Novo Nordisk Foundation, Swelife and VINNOVA - Swedish Governmental Agency for Innovation
Team
Founders
Gesynta Pharma is being actively managed by its founders, who contribute extensive experience in the fields of mPGES-1 research, medical, drug development through their work in board and management team
Board of Directors
• Co-Founder, LLM
• 20+ years in the life science industry including inhouse counsel at Pharmacia Corporation and general counsel at Vitrolife AB. Focused on transactions involving licensing, acquisitions and divestment.
• Co-founder of Cormorant Pharmaceuticals (acquired by BMS in 2016). Chairman of several pharma companies
• MD/PhD
• Co-founder and former CEO of Cormorant Pharmaceuticals AB
• Other positions include CEO of Sixera Pharma AB, VP Medical Strategy and Innovation at Camurus AB, and board positions at OxThera, Atrogi, AddBio and Cavis Technologies.
• Co-Founder, MD/PhD
• 25+ years in eicosanoid research and drug development
• 20+ years in pharmaceutical industry incl. leading positions at AZ, Biolipox, Orexo and Medivir
• Experience from all phases of drug development, senior management and strategic business development incl. successful partnering/licensing (e.g. with BI on mPGES inhibitors and J&J on arachidonic acid related targets)
• Co-Founder, MD/PhD
• 25+ years within pharmaceutical industry, incl. leading positions at AZ, Orexo, Karolinska Development and Immuneed
• Extensive experience of drug development, from discovery to clinic development
• CEO of virtual companies, non-executive Director on several pharma companies, eg NovaSAID
• Co-Founder, Professor
• Dept of Medicine, Karolinska Institutet, specialist in rheumatology and Extensive experience in eicosanoid research.
• The author of > 130 articles
• Group leader at KI (ki.se/en/meds/research-group-per-johan-jakobsson-0)• Discovered and characterized the mPGES-1 in 1998
• MD/PhD
• Specialist in Cardiology and Internal Medicine
• Formerly Vice President & Head of Cardiovascular & Gastrointestinal Therapy Areas, Global R&D, AZ
• Other board positions include Athera Biotechnology AB, IR Lab AB, Cereno Scientific AB, European Society of Cardiology
Management Team
• Co-Founder, PhD
• 20 + years in pharmaceutical and ADME research and development, 15 years in industry
• CEO, CSO, BD, staff scientist of pharmaceutical business, research and development efforts from discovery to phase III
• Corporate experience ranging from virtual companies (eg NovaSAID) to major pharma (eg Pfizer)
• Co-Founder, MD/PhD
• 25+ years in eicosanoid research and drug development
• 20+ years in pharmaceutical industry incl. leading positions at AZ, Biolipox, Orexo and Medivir
• Experience from all phases of drug development, senior management and strategic business development incl. successful partnering/licensing (e.g. with BI on mPGES inhibitors and J&J on arachidonic acid related targets)
• Co-Founder, MD/PhD
• 25+ years within pharmaceutical industry, incl. leading positions at AZ, Orexo, Karolinska Development and Immuneed
• Extensive experience of drug development, from discovery to clinic development
• CEO of virtual companies, non-executive Director on several pharma companies, eg NovaSAID
• Co-Founder, Professor
• Institute of Environmental Medicine, Karolinska Institutet
• Expert in structure, mechanism and function of MAPEG (Membrane Associated Proteins in Eicosanoid and Glutathione metabolism) enzymes
• The author of > 175 articles and book chapters• Discovered and characterised the mPGES-1 in 1998
• Co-Founder, LLM
• 20+ years in the life science industry including inhouse counsel at Pharmacia Corporation and general counsel at Vitrolife AB. Focused on transactions involving licensing, acquisitions and divestment.
• Co-founder of Cormorant Pharmaceuticals (acquired by BMS in 2016). Chairman of several pharma companies
Development team leaders
• Co-Founder, PhD
• 20 + years in pharmaceutical and ADME research and development, 15 years in industry
• CEO, CSO, BD, staff scientist of pharmaceutical business, research and development efforts from discovery to phase III
• Corporate experience ranging from virtual companies (eg NovaSAID) to major pharma (eg Pfizer)
• M.Sc. Organic Chemistry
• 20+ years experience of API manufacture within the pharmaceutical industry
• Involved in projects ranging from early phase development to commercial production
• Earlier positions: Senior Scientist, Process Chemistry and Senior Process Engineer at AstraZeneca, CMC Project Manager at Medivir
• PhD
• Responsible for the nonclinical development, consultant
• 15+ years in pharmaceutical industry e.g. project leader, group manager at AZ and senior consultant in drug development
• Extensive experience of drug development, from discovery to clinical development
• Co-Founder, MD/PhD
• 25+ years in eicosanoid research and drug development
• 20+ years in pharmaceutical industry incl. leading positions at AZ, Biolipox, Orexo and Medivir
• Experience from all phases of drug development, senior management and strategic business development incl. successful partnering/licensing (e.g. with BI on mPGES inhibitors and J&J on arachidonic acid related targets)
• MD/PhD/Associate professor
• The author of > 100 articles and book chapters
• 15+ years in pharmaceutical industry incl. leading positions at AZ, Biolipox and Orexo
• Experience from all phases of drug development
• Co-Founder, Professor
• Dept of Medicine, Karolinska Institutet, specialist in rheumatology and Extensive experience in eicosanoid research.
• The author of > 130 articles• Group leader at KI (ki.se/en/meds/research-group-per-johan-jakobsson-0)
• Discovered and characterized the mPGES-1 in 1998
• Co-Founder, MD/PhD
• 25+ years within pharmaceutical industry, incl. leading positions at AZ, Orexo, Karolinska Development and Immuneed
• Extensive experience of drug development, from discovery to clinic development
• CEO of virtual companies, non-executive Director on several pharma companies, eg NovaSAID
News
- March 19, 2019Gesynta Pharma AB broadens pipeline through acquisition of latestage discovery project
- May 18, 2018Gesynta Pharma receives 1 MSEK grant from Swelife
- April 27, 2018Gesynta Pharma accepted for prestigious incubator program
- February 26, 2018Gesynta Pharma AB secures 22 MSEK funding for completion of pre-clinical development of GS-248
- October 2, 2017Gesynta Pharma acquires development-stage mPGES-1 inhibitor program from Orexo.